AAOS2017: Assessing major wound complication rate of rivaroxaban, LMWH or placebo in THA .
A Prospective Randomized Study Comparing Oral Direct Factor Xa Inhibitor with Lowmolecular- weight Heparin for Evaluation of Surgical Wound Complications Following Total Hip Arthroplasty
958 patients scheduled for total hip arthroplasty were randomized to different groups for thromboprophylaxis. In patients <60 years of age (n=600), randomization was to either rivaroxaban, enoxaparin, or placebo. In patients 60 years of age or older (n=358), randomization was to either rivaroxaban or enoxaparin. The purpose of this study was to determine if there were any significant differences between groups in the incidence of major surgical wound complications. Results demonstrated no significant differences between groups, in either patients <60 or >60 years of age, in the rate of major surgical wound complications.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
